Impact and therapeutic potential of PPARs in Alzheimer's disease

Current Neuropharmacology

Volumn 9, Issue 4, 2011, Pages 643-650

  Heneka, Michael T ^a   Reyes Irisarri, Elisabet ^a   Hüll, Michael ^b   Kummer, Markus P ^a  

^a UNIVERSITY OF BONN   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Alzheimer's disease; Neuroinflammation; PPAR; Thiazolidinediones

Indexed keywords

2 CHLORO 5 NITROBENZANILIDE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; AMYLOID BETA PROTEIN; NONSTEROID ANTIINFLAMMATORY AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; TELMISARTAN;

ALZHEIMER DISEASE; ARTICLE; AUTOIMMUNE DISEASE; CENTRAL NERVOUS SYSTEM; DRUG ACTIVITY; ENCEPHALITIS; HUMAN; MACROPHAGE; NERVE DEGENERATION; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; RISK ASSESSMENT;

EID: 82955220499     PISSN: 1570159X     EISSN: 18756190     Source Type: Journal    
DOI: 10.2174/157015911798376325     Document Type: Article

References (99)

1. Kummer, M. P.; Heneka, M. T. PPARs in Alzheimer's Disease. PPAR Res., 2008, 2008, 403896.
2. Desvergne, B.; Wahli, W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr. Rev., 1999, 20, 649-688.
3. Michalik, L.; Auwerx, J.; Berger, J. P.; Chatterjee, V. K.; Glass, C. K.; Gonzalez, F. J.; Grimaldi, P. A.; Kadowaki, T.; Lazar, M. A.; O'Rahilly, S.; Palmer, C. N.; Plutzky, J.; Reddy, J. K.; Spiegelman, B. M.; Staels, B.; Wahli, W. International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors. Pharmacol. Rev., 2006, 58, 726-741.
4. Willson, T. M.; Lambert, M. H.; Kliewer, S. A. Peroxisome proliferator activated receptor gamma and metabolic disease. Annu. Rev. Biochem., 2001, 70, 341-367.
5. Barish, G. D.; Evans, R. M. PPARs and LXRs: atherosclerosis goes nuclear. Trends Endocrinol. Metab., 2004, 15, 158-165.
6. Pascual, G.; Fong, A. L.; Ogawa, S.; Gamliel, A.; Li, A. C.; Perissi, V.; Rose, D. W.; Willson, T. M.; Rosenfeld, M. G.; Glass, C. K. A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-gamma. Nature, 2005, 437, 759-763.
7. Diradourian, C.; Girard, J.; Pegorier, J. P. Phosphorylation of PPARs: from molecular characterization to physiological relevance. Biochimie, 2005, 87, 33-38.
8. Adams, M.; Reginato, M. J.; Shao, D.; Lazar, M. A.; Chatterjee, V. K. Transcriptional activation by peroxisome proliferator-activated receptor gamma is inhibited by phosphorylation at a consensus mitogen-activated protein kinase site. J. Biol. Chem., 1997, 272, 5128-5132.
9. Shao, D.; Rangwala, S. M.; Bailey, S. T.; Krakow, S. L.; Reginato, M. J.; Lazar, M. A. Interdomain communication regulating ligand binding by PPAR-gamma. Nature, 1998, 396, 377-380.
10. Camp, H. S.; Tafuri, S. R.; Leff, T. c-Jun N-terminal kinase phosphorylates peroxisome proliferator-activated receptor-gamma1 and negatively regulates its transcriptional activity147. Endocrinology, 1999, 140, 392-397.
11. Hu, E.; Kim, J. B.; Sarraf, P.; Spiegelman, B. M. Inhibition of adipogenesis through MAP kinase-mediated phosphorylation of PPARgamma148. Science, 1996, 274, 2100-2103.
12. Camp, H. S.;Tafuri, S. R. Regulation of peroxisome proliferatoractivated receptor gamma activity by mitogen-activated protein kinase. J. Biol. Chem., 1997, 272, 10811-10816.
13. Floyd, Z. E.;Stephens, J. M. Interferon-gamma-mediated activation and ubiquitin-proteasome-dependent degradation of PPARgamma in adipocytes. J. Biol. Chem., 2002, 277, 4062-4068.
14. Hauser, S.; Adelmant, G.; Sarraf, P.; Wright, H. M.; Mueller, E.; Spiegelman, B. M. Degradation of the peroxisome proliferatoractivated receptor gamma is linked to ligand-dependent activation. J. Biol. Chem., 2000, 275, 18527-18533.
15. Yamashita, D.; Yamaguchi, T.; Shimizu, M.; Nakata, N.; Hirose, F.; Osumi, T. The transactivating function of peroxisome proliferator activated receptor gamma is negatively regulated by SUMO conjugation in the amino-terminal domain. Genes Cells, 2004, 9, 1017-1029.
16. Floyd, Z. E.;Stephens, J. M. Control of peroxisome proliferatoractivated receptor gamma2 stability and activity by SUMOylation Obes. Res., 2004, 12, 921-928.
17. Burgermeister, E.; Chuderland, D.; Hanoch, T.; Meyer, M.; Liscovitch, M.; Seger, R. Interaction with MEK causes nuclear export and downregulation of peroxisome proliferator-activated receptor gamma. Mol. Cell Biol., 2007, 27, 803-817.
18. Shibuya, A.; Wada, K.; Nakajima, A.; Saeki, M.; Katayama, K.; Mayumi, T.; Kadowaki, T.; Niwa, H.; Kamisaki, Y. Nitration of PPARgamma inhibits ligand-dependent translocation into the nucleus in a macrophage-like cell line, RAW 264. FEBS Lett., 2002, 525, 43-47.
19. Daynes, R. A.;Jones, D. C. Emerging roles of PPARs in inflammation and immunity. Nat. Rev. Immunol., 2002, 2, 748-759.
20. Ghisletti, S.; Huang, W.; Ogawa, S.; Pascual, G.; Lin, M. E.; Willson, T. M.; Rosenfeld, M. G.; Glass, C. K. Parallel SUMOylationdependent pathways mediate gene and signal-specific transrepression by LXRs and PPARgamma. Mol. Cell, 2007, 25, 57-70.
21. Ogawa, S.; Lozach, J.; Benner, C.; Pascual, G.; Tangirala, R. K.; Westin, S.; Hoffmann, A.; Subramaniam, S.; David, M.; Rosenfeld, M. G.; Glass, C. K. Molecular determinants of crosstalk between nuclear receptors and toll-like receptors. Cell, 2005, 122, 707-721.
22. Krey, G.; Braissant, O.; L'Horset, F.; Kalkhoven, E.; Perroud, M.; Parker, M. G.; Wahli, W. Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferatoractivated receptors by coactivator-dependent receptor ligand assay. Mol. Endocrinol., 1997, 11, 779-791.
23. Bernardo, A.;Minghetti, L. PPAR-gamma agonists as regulators of microglial activation and brain inflammation. Curr. Pharm. Des, 2006, 12, 93-109.
24. Keller, J. M.; Collet, P.; Bianchi, A.; Huin, C.; Bouillaud Kremarik, P.; Becuwe, P.; Schohn, H.; Domenjoud, L.; Dauca, M. Implications of peroxisome proliferator-activated receptors (PPARS) in development, cell life status and disease. Int. J. Dev. Biol., 2000, 44, 429-442.
25. Mukherjee, R.; Jow, L.; Croston, G. E.; Paterniti, J. R., Jr. Identification, characterization, and tissue distribution of human peroxisome proliferator-activated receptor (PPAR) isoforms PPARgamma2 versus PPARgamma1 and activation with retinoid X receptor agonists and antagonists. J. Biol. Chem., 1997, 272, 8071 8076.
26. Auboeuf, D.; Rieusset, J.; Fajas, L.; Vallier, P.; Frering, V.; Riou, J. P.; Staels, B.; Auwerx, J.; Laville, M.; Vidal, H. Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-alpha in humans: no alteration in adipose tissue of obese and NIDDM patients. Diabetes, 1997, 46, 1319-1327.
27. Palmer, C. N.; Hsu, M. H.; Griffin, K. J.; Raucy, J. L.; Johnson, E. F. Peroxisome proliferator activated receptor-alpha expression in human liver. Mol. Pharmacol., 1998, 53, 14-22.
28. Braissant, O.; Foufelle, F.; Scotto, C.; Dauca, M.; Wahli, W. Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha,-beta, and-gamma in the adult rat. Endocrinology, 1996, 137, 354-366.
29. Moreno, S.; Farioli-Vecchioli, S.; Ceru, M. P. Immunolocalization of peroxisome proliferator-activated receptors and retinoid X receptors in the adult rat CNS. Neuroscience, 2004, 123, 131-145.
30. Woods, J. W.; Tanen, M.; Figueroa, D. J.; Biswas, C.; Zycband, E.; Moller, D. E.; Austin, C. P.; Berger, J. P. Localization of PPARdelta in murine central nervous system: expression in oligodendrocytes and neurons. Brain Res., 2003, 975, 10-21.
31. Gofflot, F.; Chartoire, N.; Vasseur, L.; Heikkinen, S.; Dembele, D.; Le Merrer, J.; Auwerx, J. Systematic gene expression mapping clusters nuclear receptors according to their function in the brain. Cell, 2007, 131, 405-418.
32. Basu-Modak, S.; Braissant, O.; Escher, P.; Desvergne, B.; Honegger, P.; Wahli, W. Peroxisome proliferator-activated receptor beta regulates acyl-CoA synthetase 2 in reaggregated rat brain cell cultures. J. Biol. Chem., 1999, 274, 35881-35888.
33. Cimini, A.; Cristiano, L.; Colafarina, S.; Benedetti, E.; Di Loreto, S.; Festuccia, C.; Amicarelli, F.; Canuto, R. A.; Ceru, M. P. PPARgamma dependent effects of conjugated linoleic acid on the human glioblastoma cell line (ADF). Int. J. Cancer, 2005, 117, 923-933.
34. Heneka, M. T.; Klockgether, T.; Feinstein, D. L. Peroxisome proliferator-activated receptor-gamma ligands reduce neuronal inducible nitric oxide synthase expression and cell death in vivo. J. Neurosci., 2000, 20, 6862-6867.
35. Inestrosa, N. C.; Godoy, J. A.; Quintanilla, R. A.; Koenig, C. S.; Bronfman, M. Peroxisome proliferator-activated receptor gamma is expressed in hippocampal neurons and its activation prevents betaamyloid neurodegeneration: role of Wnt signaling. Exp. Cell Res., 2005, 304, 91-104.
36. Park, K. S.; Lee, R. D.; Kang, S. K.; Han, S. Y.; Park, K. L.; Yang, K. H.; Song, Y. S.; Park, H. J.; Lee, Y. M.; Yun, Y. P.; Oh, K. W.; Kim, D. J.; Yun, Y. W.; Hwang, S. J.; Lee, S. E.; Hong, J. T. Neuronal differentiation of embryonic midbrain cells by upregulation of peroxisome proliferator-activated receptor-gamma via the JNKdependent pathway. Exp. Cell Res., 2004, 297, 424-433.
37. Smith, S. A.; Monteith, G. R.; Robinson, J. A.; Venkata, N. G.; May, F. J.; Roberts-Thomson, S. J. Effect of the peroxisome proliferator activated receptor beta activator GW0742 in rat cultured cerebellar granule neurons. J. Neurosci. Res., 2004, 77, 240-249.
38. Zhao, X. R.; Strong, R.; Zhang, J.; Sun, G. H.; Tsien, J. Z.; Cui, Z. Z.; Grotta, J. C.; Aronowski, J. Neuronal PPAR gamma deficiency increases susceptibility to brain damage after cerebral ischemia. J. Neurosci., 2009, 29, 6186-6195.
39. Dill, J.; Patel, A. R.; Yang, X. L.; Bachoo, R.; Powell, C. M.; Li, S. X. A molecular mechanism for Ibuprofen-Mediated RhoA inhibition in neurons. J. Neurosci., 2010, 30, 963-972.
40. Cimini, A.; Bernardo, A.; Cifone, M. G.; Di Marzio, L.; Di Loreto, S. TNFalpha downregulates PPARdelta expression in oligodendrocyte progenitor cells: implications for demyelinating diseases. Glia, 2003, 41, 3-14.
41. Saluja, I.; Granneman, J. G.; Skoff, R. P. PPAR delta agonists stimulate oligodendrocyte differentiation in tissue culture. Glia, 2001, 33, 191-204.
42. Cristiano, L.; Cimini, A.; Moreno, S.; Ragnelli, A. M.; Paola, C. M. Peroxisome proliferator-activated receptors (PPARs) and related transcription factors in differentiating astrocyte cultures. Neuroscience, 2005, 131, 577-587.
43. Cullingford, T. E.; Bhakoo, K.; Peuchen, S.; Dolphin, C. T.; Patel, R.; Clark, J. B. Distribution of mRNAs encoding the peroxisome proliferator-activated receptor alpha, beta, and gamma and the retinoid X receptor alpha, beta, and gamma in rat central nervous system. J. Neurochem., 1998, 70, 1366-1375.
44. Farioli-Vecchioli, S.; Moreno, S.; Ceru, M. P. Immunocytochemical localization of acyl-CoA oxidase in the rat central nervous system. J. Neurocytol., 2001, 30, 21-33.
45. Tanzi, R. E.;Bertram, L. Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective. Cell, 2005, 120, 545-555.
46. Price, D. L.; Tanzi, R. E.; Borchelt, D. R.; Sisodia, S. S. Alzheimer's disease: genetic studies and transgenic models. Annu. Rev. Genet., 1998, 32, 461-493.
47. Hull, M.; Lieb, K.; Fiebich, B. L. Pathways of inflammatory activation in Alzheimer's disease: potential targets for disease modifying drugs. Curr. Med. Chem., 2002, 9, 83-88.
48. Akiyama, H.; Barger, S.; Barnum, S.; Bradt, B.; Bauer, J.; Cole, G. M.; Cooper, N. R.; Eikelenboom, P.; Emmerling, M.; Fiebich, B. L.; Finch, C. E.; Frautschy, S.; Griffin, W. S.; Hampel, H.; Hull, M.; Landreth, G.; Lue, L.; Mrak, R.; Mackenzie, I. R.; McGeer, P. L.; O'Banion, M. K.; Pachter, J.; Pasinetti, G.; Plata-Salaman, C.; Rogers, J.; Rydel, R.; Shen, Y.; Streit, W.; Strohmeyer, R.; Tooyoma, I.; Van Muiswinkel, F. L.; Veerhuis, R.; Walker, D.; Webster, S.; Wegrzyniak, B.; Wenk, G.; Wyss-Coray, T. Inflammation and Alzheimer's disease. Neurobiol. Aging, 2000, 21, 383-421.
49. Sly, L. M.; Krzesicki, R. F.; Brashler, J. R.; Buhl, A. E.; McKinley, D. D.; Carter, D. B.; Chin, J. E. Endogenous brain cytokine mRNA and inflammatory responses to lipopolysaccharide are elevated in the Tg2576 transgenic mouse model of Alzheimer's disease. Brain Res. Bull., 2001, 56, 581-588.
50. Heneka, M. T.; O'Banion, M. K. Inflammatory processes in Alzheimer's disease. J. Neuroimmunol., 2007, 184, 69-91.
51. Heneka, M. T.; Wiesinger, H.; Dumitrescu-Ozimek, L.; Riederer, P.; Feinstein, D. L.; Klockgether, T. Neuronal and glial coexpression of argininosuccinate synthetase and inducible nitric oxide synthase in Alzheimer disease. J. Neuropathol. Exp. Neurol., 2001, 60, 906-916.
52. Lee, S. C.; Zhao, M. L.; Hirano, A.; Dickson, D. W. Inducible nitric oxide synthase immunoreactivity in the Alzheimer disease hippocampus: association with Hirano bodies, neurofibrillary tangles, and senile plaques. J. Neuropathol. Exp. Neurol., 1999, 58, 1163-1169.
53. Vodovotz, Y.; Lucia, M. S.; Flanders, K. C.; Chesler, L.; Xie, Q. W.; Smith, T. W.; Weidner, J.; Mumford, R.; Webber, R.; Nathan, C.; Roberts, A. B.; Lippa, C. F.; Sporn, M. B. Inducible nitric oxide synthase in tangle-bearing neurons of patients with Alzheimer's disease. J. Exp. Med., 1996, 184, 1425-1433.
54. de la Monte, S. M.;Wands, J. R. Molecular indices of oxidative stress and mitochondrial dysfunction occur early and often progress with severity of Alzheimer's disease. J. Alzheimers Dis., 2006, 9, 167-181.
55. Heneka, M. T.; Landreth, G. E.; Feinstein, D. L. Role for peroxisome proliferator-activated receptor-gamma in Alzheimer's disease. Ann. Neurol., 2001, 49, 276.
56. Kielian, T.; Drew, P. D. Effects of peroxisome proliferatoractivated receptor-gamma agonists on central nervous system inflammation. J. Neurosci. Res., 2003, 71, 315-325.
57. Landreth, G. E.;Heneka, M. T. Anti-inflammatory actions of peroxisome proliferator-activated receptor gamma agonists in Alzheimer's disease. Neurobiol. Aging, 2001, 22, 937-944.
58. in't Veld, V.; Ruitenberg, A.; Hofman, A.; Launer, L. J.; van Duijn, C. M.; Stijnen, T.; Breteler, M. M.; Stricker, B. H. Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. N. Engl. J. Med., 2001, 345, 1515-1521.
59. Lehmann, J. M.; Lenhard, J. M.; Oliver, B. B.; Ringold, G. M.; Kliewer, S. A. Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J. Biol. Chem., 1997, 272, 3406-3410.
60. Heneka, M. T.; Feinstein, D. L.; Galea, E.; Gleichmann, M.; Wullner, U.; Klockgether, T. Peroxisome proliferator-activated receptor gamma agonists protect cerebellar granule cells from cytokineinduced apoptotic cell death by inhibition of inducible nitric oxide synthase. J. Neuroimmunol., 1999, 100, 156-168.
61. Combs, C. K.; Johnson, D. E.; Karlo, J. C.; Cannady, S. B.; Landreth, G. E. Inflammatory mechanisms in Alzheimer's disease: inhibition of beta-amyloid-stimulated proinflammatory responses and neurotoxicity by PPARgamma agonists. J. Neurosci., 2000, 20, 558-567.
62. Kim, E. J.; Kwon, K. J.; Park, J. Y.; Lee, S. H.; Moon, C. H.; Baik, E. J. Effects of peroxisome proliferator-activated receptor agonists on LPS-induced neuronal death in mixed cortical neurons: associated with iNOS and COX-2. Brain Res., 2002, 941, 1-10.
63. Luna-Medina, R.; Cortes-Canteli, M.; Alonso, M.; Santos, A.; Martinez, A.; Perez-Castillo, A. Regulation of inflammatory response in neural cells in vitro by thiadiazolidinones derivatives through peroxisome proliferator-activated receptor gamma activation. J. Biol. Chem., 2005, 280, 21453-21462.
64. Heneka, M. T.; Gavrilyuk, V.; Landreth, G. E.; O'Banion, M. K.; Weinberg, G.; Feinstein, D. L. Noradrenergic depletion increases inflammatory responses in brain: effects on IkappaB and HSP70 expression. J. Neurochem., 2003, 85, 387-398.
65. Maeshiba, Y.; Kiyota, Y.; Yamashita, K.; Yoshimura, Y.; Motohashi, M.; Tanayama, S. Disposition of the new antidiabetic agent pioglitazone in rats, dogs, and monkeys. Arzneimittelforschung, 1997, 47, 29-35.
66. Yan, Q.; Zhang, J.; Liu, H.; Babu-Khan, S.; Vassar, R.; Biere, A. L.; Citron, M.; Landreth, G. Anti-inflammatory drug therapy alters beta-amyloid processing and deposition in an animal model of Alzheimer's disease. J. Neurosci., 2003, 23, 7504-7509.
67. Heneka, M. T.; Sastre, M.; Dumitrescu-Ozimek, L.; Dewachter, I.; Walter, J.; Klockgether, T.; van Leuven, F. Focal glial activation coincides with increased BACE1 activation and precedes amyloid plaque deposition in APP[V717I] transgenic mice. J. Neuroinflamm., 2005, 2, 22.
68. Sastre, M.; Klockgether, T.; Heneka, M. T. Contribution of inflammatory processes to Alzheimer's disease: molecular mechanisms. Int. J. Dev. Neurosci., 2006, 24, 167-176.
69. Sastre, M.; Dewachter, I.; Landreth, G. E.; Willson, T. M.; Klockgether, T.; van Leuven, F.; Heneka, M. T. Nonsteroidal antiinflammatory drugs and peroxisome proliferator-activated receptorgamma agonists modulate immunostimulated processing of amyloid precursor protein through regulation of beta-secretase. J. Neurosci., 2003, 23, 9796-9804.
70. Camacho, I. E.; Serneels, L.; Spittaels, K.; Merchiers, P.; Dominguez, D.; De Strooper, B. Peroxisome-proliferator-activated receptor gamma induces a clearance mechanism for the amyloid-beta peptide. J. Neurosci., 2004, 24, 10908-10917.
71. Weggen, S.; Eriksen, J. L.; Das, P.; Sagi, S. A.; Wang, R.; Pietrzik, C. U.; Findlay, K. A.; Smith, T. E.; Murphy, M. P.; Bulter, T.; Kang, D. E.; Marquez-Sterling, N.; Golde, T. E.; Koo, E. H. A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature, 2001, 414, 212-216.
72. Eriksen, J. L.; Sagi, S. A.; Smith, T. E.; Weggen, S.; Das, P.; McLendon, D. C.; Ozols, V. V.; Jessing, K. W.; Zavitz, K. H.; Koo, E. H.; Golde, T. E. NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower A beta 42 in vivo. J. Clin. Investig., 2003, 112, 440-449.
73. Morihara, T.; Teter, B.; Yang, F.; Lim, G. P.; Boudinot, S.; Boudinot, F. D.; Frautschy, S. A.; Cole, G. M. Ibuprofen suppresses interleukin-1beta induction of pro-amyloidogenic alpha1-antichymotrypsin to ameliorate beta-amyloid (Abeta) pathology in Alzheimer's models. Neuropsychopharmacology, 2005, 30, 1111-1120.
74. Lanz, T. A.; Fici, G. J.; Merchant, K. M. Lack of specific amyloidbeta(1-42) suppression by nonsteroidal anti-inflammatory drugs in young, plaque-free Tg2576 mice and in guinea pig neuronal cultures. J. Pharmacol. Exp. Ther., 2005, 312, 399-406.
75. Fuentealba, R. A.; Farias, G.; Scheu, J.; Bronfman, M.; Marzolo, M. P.; Inestrosa, N. C. Signal transduction during amyloid-betapeptide neurotoxicity: role in Alzheimer disease. Brain Res. Brain Res. Rev., 2004, 47, 275-289.
76. Zhao, X.; Ou, Z.; Grotta, J. C.; Waxham, N.; Aronowski, J. Peroxisome proliferator-activated receptor-gamma (PPARgamma) activation protects neurons from NMDA excitotoxicity. Brain Res., 2006, 1073-1074, 460-469.
77. Wada, K.; Nakajima, A.; Katayama, K.; Kudo, C.; Shibuya, A.; Kubota, N.; Terauchi, Y.; Tachibana, M.; Miyoshi, H.; Kamisaki, Y.; Mayumi, T.; Kadowaki, T.; Blumberg, R. S. Peroxisome proliferator activated receptor gamma-mediated regulation of neural stem cell proliferation and differentiation. J. Biol. Chem., 2006, 281, 12673-12681.
78. Pedersen, W. A.; McMillan, P. J.; Kulstad, J. J.; Leverenz, J. B.; Craft, S.; Haynatzki, G. R. Rosiglitazone attenuates learning and memory deficits in Tg2576 Alzheimer mice. Exp. Neurol., 2006, 199, 265-273.
79. Escribano, L.; Simon, A. M.; Gimeno, E.; Cuadrado-Tejedor, M.; de Maturana, R. L.; Garcia-Osta, A.; Ricobaraza, A.; Perez Mediavilla, A.; Rio, J. D.; Frechilla, D. Rosiglitazone Rescues Memory Impairment in Alzheimer's Transgenic Mice: Mechanisms involving a Reduced amyloid and Tau pathology. Neuropsychopharmacology, 2010, 35(7), 1593-604.
80. Du, J.; Zhang, L.; Liu, S. B.; Zhang, C.; Huang, X. Q.; Li, J.; Zhao, N. M.; Wang, Z. PPAR gamma transcriptionally regulates the expression of insulin-degrading enzyme in primary neurons. Biochem. Biophys. Res. Commun., 2009, 383, 485-490.
81. Qiu, W. Q.; Folstein, M. F. Insulin, insulin-degrading enzyme and amyloid-beta peptide in Alzheimer's disease: review and hypothesis. Neurobiol. Aging, 2006, 27, 190-198.
82. Mogi, M.; Li, J. M.; Tsukuda, K.; Iwanami, J.; Min, L. J.; Sakata, A.; Fujita, T.; Iwai, M.; Horiuchi, M. Telmisartan prevented cognitive decline partly due to PPAR-gamma activation. Biochem. Biophys. Res. Commun., 2008, 375, 446-449.
83. Du, J.; Sun, B.; Chen, K.; Fan, L.; Wang, Z. Antagonist of peroxisome proliferator-activated receptor gamma induces cerebellar amyloid-beta levels and motor dysfunction in APP/PS1 transgenic mice. Biochem. Biophys. Res. Commun., 2009, 384, 357-361.
84. Scacchi, R.; Pinto, A.; Gambina, G.; Rosano, A.; Corbo, R. M. The peroxisome proliferator-activated receptor gamma (PPAR-gamma2) Pro12Ala polymorphism is associated with higher risk for Alzheimer's disease in octogenarians. Brain Res., 2007, 1139, 1-5.
85. Hamilton, G.; Proitsi, P.; Jehu, L.; Morgan, A.; Williams, J.; O'Donovan, M. C.; Owen, M. J.; Powell, J. F.; Lovestone, S. Candidate gene association study of insulin signaling genes and Alzheimer's disease: evidence for SOS2, PCK1, and PPARgamma as susceptibility loci. Am. J. Med. Genet. B Neuropsychiatr. Genet., 2007, 144, 508-516.
86. Koivisto, A. M.; Helisalmi, S.; Pihlajamaki, J.; Hiltunen, M.; Koivisto, K.; Moilanen, L.; Kuusisto, J.; Helkala, E. L.; Hanninen, T.; Kervinen, K.; Kesaniemi, Y. A.; Laakso, M.; Soininen, H. Association analysis of peroxisome proliferator-activated receptor gamma polymorphisms and late onset Alzheimer's disease in the Finnish population. Dement. Geriatr. Cogn. Disord., 2006, 22, 449-453.
87. Sauder, S.; Kolsch, H.; Lutjohann, D.; Schulz, A.; von Bergmann, K.; Maier, W.; Heun, R. Influence of peroxisome proliferator-activated receptor gamma gene polymorphism on 24S-hydroxycholesterol levels in Alzheimer's patients. J. Neural Trans., 2005, 112, 1381-1389.
88. Yao, L.; Li, K.; Zhang, L.; Yao, S.; Piao, Z.; Song, L. Influence of the Pro12Ala polymorphism of PPAR-gamma on age at onset and sRAGE levels in Alzheimer's disease. Brain Res., 2009, 1291, 133-139.
89. West, N. A.; Haan, M. N.; Herman, W. H.; Morgenstern, H. Association between the Pro12Ala polymorphism and dementia or cognitive impairment. Diabetes, 2007, 56, A647.
90. Johnson, W.; Harris, S. E.; Starr, J. M.; Whalley, L. J.; Deary, I. J. PPARG Pro12Ala genotype and risk of cognitive decline in elders? Maybe with diabetes. Neurosci. Lett., 2008, 434, 50-55.
91. Helisalmi, S.; Tarvainen, T.; Vepsalainen, S.; Koivisto, A. M.; Hiltunen, M.; Soininen, H. Lack of genetic association between PPARG gene polymorphisms and Finnish late-onset Alzheimer's disease. Neurosci. Lett., 2008, 441, 233-236.
92. Watson, G. S.; Cholerton, B. A.; Reger, M. A.; Baker, L. D.; Plymate, S. R.; Asthana, S.; Fishel, M. A.; Kulstad, J. J.; Green, P. S.; Cook, D. G.; Kahn, S. E.; Keeling, M. L.; Craft, S. Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study. Am. J. Geriatr. Psychiatry, 2005, 13, 950-958.
93. Risner, M. E.; Saunders, A. M.; Altman, J. F.; Ormandy, G. C.; Craft, S.; Foley, I. M.; Zvartau-Hind, M. E.; Hosford, D. A.; Roses, A. D. Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease. Pharmacogenom. J., 2006, 6, 246-254.
94. Strum, J. C.; Shehee, R.; Virley, D.; Richardson, J.; Mattie, M.; Selley, P.; Ghosh, S.; Nock, C.; Saunders, A.; Roses, A. Rosiglitazone induces mitochondrial biogenesis in mouse brain. J. Alzheimers Dis., 2007, 11, 45-51.
95. Feinstein, D. L.; Spagnolo, A.; Akar, C.; Weinberg, G.; Murphy, P.; Gavrilyuk, V.; Dello, R. C. Receptor-independent actions of PPAR thiazolidinedione agonists: is mitochondrial function the key? Biochem. Pharmacol., 2005, 70, 177-188.
96. Craft, S.; Asthana, S.; Schellenberg, G.; Cherrier, M.; Baker, L. D.; Newcomer, J.; Plymate, S.; Latendresse, S.; Petrova, A.; Raskind, M.; Peskind, E.; Lofgreen, C.; Grimwood, K. Insulin metabolism in Alzheimer's disease differs according to apolipoprotein E genotype and gender. Neuroendocrinology, 1999, 70, 146-152.
97. Craft, S.; Asthana, S.; Schellenberg, G.; Baker, L.; Cherrier, M.; Boyt, A. A.; Martins, R. N.; Raskind, M.; Peskind, E.; Plymate, S. Insulin effects on glucose metabolism, memory, and plasma amyloid precursor protein in Alzheimer's disease differ according to apolipoprotein-E genotype. Ann. N. Y. Acad. Sci., 2000, 903, 222-228.
98. Kuusisto, J.; Koivisto, K.; Mykkanen, L.; Helkala, E. L.; Vanhanen, M.; Hanninen, T.; Kervinen, K.; Kesaniemi, Y. A.; Riekkinen, P. J.; Laakso, M. Association between features of the insulin resistance syndrome and Alzheimer's disease independently of apolipoprotein E4 phenotype: cross sectional population based study. BMJ, 1997, 315, 1045-1049.
99. Sato, T.; Hanyu, H.; Hirao, K.; Kanetaka, H.; Sakurai, H.; Iwamoto, T. Efficacy of PPAR-gamma agonist pioglitazone in mild Alzheimer disease. Neurobiol. Aging, 2009, 32(9), 1626-33.